In order to prevent spam,
this email address cannot be copied.
Schizophrenia Research Forum: Researcher Profile - Maria J Arranz
Schizophrenia Research Forum - A Catalyst for Creative Thinking
Home Profile Membership/Get Newsletter Log In Contact Us
 For Patients & Families
What's New
Recent Updates
SRF Papers
Current Papers
Search All Papers
Search Comments
Research News
Conference News
Plain English
Current Hypotheses
Idea Lab
Online Discussions
Virtual Conferences
What We Know
Animal Models
Drugs in Trials
Research Tools
Community Calendar
General Information
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
SRF Team
Advisory Board
Support Us
How to Cite
Fan (E)Mail
The Schizophrenia Research Forum web site is sponsored by the Brain and Behavior Research Foundation and was created with funding from the U.S. National Institute of Mental Health.
Researcher Profile - Maria J Arranz

First Name:Maria J
Last Name:Arranz
Advanced Degrees:PhD
Affiliation:Institute of Psychiatry
Department:Clinical Neuropharmacology
Street Address 1:1, Windsor Walk
Street Address 2:PO51
Zip/Postal Code:SE5 8AF
Country/Territory:United Kingdom
Email Address:
(view policy) 
Clinical Interests:
Neurodevelopmental disorders (e.g., 22q11 deletion syndromes), Schizophrenia, Drug abuse, Bipolar disorder , Depression
Research Focus:
Bioinformatics/Statistics, Neurodevelopment, Pharamacology, Proteomics, Genetics, Glutamatergic transmission, Animal models, Molecular and Cell biology, DNA microrrays, Drug screening, Signal transduction, Stem cells
Work Sector(s):
Research institute
Web Sites:
Reasearcher Bio
For the past 13 years I have been working on genetics and pharmacogenetics of psychiatric disorders. I have coordinated research which lead to the confirmation of the genetic influence on treatment response and that lead to development of genetic prediction tests for antipsychotic drugs. I am also interested in differential expression and epigenetic factors related to psychotropic treatment variability.
Top Papers
Kerwin R.W., Arranz MJ (2004). Pharmacogenetics in Psychiatry (Chapter 2). In Seminars in Clinical Neuropharmacology, Edited by David J. King. Gaskell Press (UK).

Kerwin RW, Arranz MJ. (2002). Psychopharmacogenetics. In Psychiatric Genetics and Genomics (chapter 14: 397-414). Edited by P.McGuffin, M.J.Owen & I.I.Gottesman. Oxford University Press (UK).

Arranz MJ, Munro J, Birkett J, Bolonna A, Mancama D, Sodhi M, Lesch KP, Meyer JFW, Sham P, Collier DA, Murray RM, Kerwin RW (2000). Pharmacogenetic prediction of clozapine response. Lancet, 355 (9215): 1615-1616.

Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J, Kirov G, Collier DA and Kerwin RW (1998). Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Molecular Psychiatry, 3: 61-66

Arranz MJ, Collier D, Sodhi M, Ball D, Roberts G, Price J, Sham P and Kerwin R (1995).- Association between clozapine response and allelic variation in the 5-HT2A receptor gene. Lancet , 346: 281-282

What are the top three papers (not yours) you have read recently?
Harrison & Weinberger (2005). Schizophrenia genes, gene expression, and neuropathology, on the matter of their convergence. Mol.Psychiatry, 10: 40-68

Rapoport et al., (2005). The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry, 10: 434-449

Weber et al., (2005). Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells
If resources were not limited, what research projects would you pursue?
Pharmacogenomics of antipsychotics at large scale, with large clinical cohorts for association studies, and stem cells models for expression studies.
What is your leading hypothesis?
Genetic factors have an important influence in disease aetiology and treatment variability

Research Participants
Copyright © 2005- 2016 Schizophrenia Research Forum Privacy Policy Disclaimer Disclosure Copyright